Monoclonal Antibodies for Multiple Sclerosis Treatment

Authors

  • Filipe Palavra Institute for Biomedical Imaging and Life Sciences, CNC. IBILI Research Unit. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal. Institute for Nuclear Sciences Applied to Health (ICNAS). Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal.

DOI:

https://doi.org/10.20344/amp.6486

Keywords:

Antibodies, Monoclonal, Clinical Trials, Multiple Sclerosis.

Abstract

Since their introduction in medical therapy, in the last quarter of the 20th century, monoclonal antibodies have gained an increasing importance in the treatment of various diseases. Neurology has been one of the medical specialties benefiting of the therapeutic potential of these monoclonal antibodies and certain neurological conditions may now contain such drugs in their therapeutic algorithms. Multiple sclerosis is one of these diseases and, in addition to the monoclonal antibodies already licensed for clinical use, several others are in development for future utilization in this specific area. The future will certainly pass through this kind of drugs and, in this article, a review of the most relevant data related to monoclonal antibodies already in use and also in clinical development for multiple sclerosis treatment will be performed.

Downloads

Download data is not yet available.

Downloads

Published

2015-09-11

How to Cite

1.
Palavra F. Monoclonal Antibodies for Multiple Sclerosis Treatment. Acta Med Port [Internet]. 2015 Sep. 11 [cited 2022 Nov. 30];28(5):640-51. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/6486

Issue

Section

Review Articles